(HealthDay)—The effectiveness of mRNA vaccination against COVID-19-associated hospitalization is sustained over a 24-week period, according to research published in the Aug. 18 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Mark W. Tenforde, M.D., Ph.D., how to buy orlistat overnight shipping no prescription from the CDC COVID-19 Response Team, and colleagues assessed the duration of mRNA vaccine effectiveness (Pfizer-BioNTech or Moderna) against COVID-19-associated hospitalization among adults aged 18 years and older in an evaluation at 21 hospitals in 18 states.
Data were included for 3,089 hospitalized adults (1,194 COVID-19 case patients and 1,895 non-COVID-19 controls) with a median age of 59 years; 21.1 percent had an immunocompromising condition. The researchers found that 11.8 and 52.1 percent of case patients and controls were fully vaccinated (receipt of second dose ≥14 days before illness onset), with a median interval of 65 days after receipt of the second dose. During the full surveillance period, vaccine effectiveness against COVID-19-associated hospitalization was 86 and 90 percent overall and among adults without immunocompromising conditions, respectively. Vaccine effectiveness against COVID-19-associated hospitalization was 86 and 84 percent at two to 12 weeks and 13 to 24 weeks from receipt of the second vaccine dose, respectively. In whole-genome sequencing of 454 case-patient specimens, 53.3 and 16.3 percent belonged to the alpha and delta lineage, respectively.
Source: Read Full Article